ArticleCureus2025
Dosimetry, Toxicity, and Outcomes of Medically Inoperable Endometrial Cancer Treated With Definitive External Beam Radiation Therapy and Brachytherapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOur goal was to evaluate the dosimetry, toxicity, and outcomes of medically inoperable endometrial cancer patients treated with external beam radiation therapy (EBRT) and brachytherapy.
methodsA single-institution retrospective chart review was performed to identify patients with medically inoperable endometrial cancer who underwent EBRT and brachytherapy from 2009 to 2024. Patient demographics, tumor characteristics, and radiation dosimetry data were collected. Toxicities were defined using the Common Terminology Criteria for Adverse Events (CTCAE version 5.0). Outcomes evaluated included overall survival (OS) and recurrence-free survival (RFS).
resultsA total of 19 patients were included in the study. Median body mass index (BMI), Charlson comorbidity index, and Karnofsky performance status (KPS) were 50 kg/m
conclusionsBrachytherapy with EBRT can be used to treat medically inoperable endometrial cancer patients with a minimal risk of severe toxicity. OS may be decreased with extended total treatment time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.